{"id":"hydronidone-270mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Osteoporosis"},{"rate":null,"effect":"Immunosuppression/increased infection risk"},{"rate":null,"effect":"Adrenal suppression"}]},"_chembl":{"chemblId":"CHEMBL4297288","moleculeType":"Small molecule","molecularWeight":"201.22"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a synthetic corticosteroid, hydronidone exerts anti-inflammatory effects through glucocorticoid receptor activation, leading to decreased production of inflammatory cytokines and immune cell activation. It is used to manage inflammatory and autoimmune conditions where suppression of the immune response is therapeutically beneficial.","oneSentence":"Hydronidone is a corticosteroid that reduces inflammation and suppresses immune responses by binding to glucocorticoid receptors.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:55:02.221Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders (specific indication under phase 3 evaluation not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT07412236","phase":"PHASE3","title":"A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-30","conditions":"Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B","enrollment":1208},{"nctId":"NCT02499562","phase":"PHASE2","title":"A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis","status":"COMPLETED","sponsor":"Shanghai Genomics, Inc.","startDate":"2015-06-25","conditions":"Hepatitis B, Chronic","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Hydronidone (270mg)","genericName":"Hydronidone (270mg)","companyName":"Beijing Continent Pharmaceutical Co, Ltd.","companyId":"beijing-continent-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydronidone is a corticosteroid that reduces inflammation and suppresses immune responses by binding to glucocorticoid receptors. Used for Inflammatory and autoimmune disorders (specific indication under phase 3 evaluation not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}